ID 4689 -
	
		
			Kwas dokozaheksaenowy, Kwas eikozapentaenowy
		
		
		
	 
PL: Kwas dokozaheksaenowy, Kwas eikozapentaenowy
EN: DHA+EPA - long chain omega 3 fatty acids
Pdf: eicosapentaenoic acid
 
	Oświadczenie (2)
	
		
			-  układu krążenia
 
		
			-  obniżające poziom cholesterolu
 
		
			-  zdrowie serca
 
		
			-  metabolizm system sercowo-naczyniowych (cholesterol, trójglicerydy)
 
		
	
 
        
        
                
1. Charakterystyka żywności / składnika
                
                
                    The food constituent which is the subject of the health claims is mixed long-chain n-3 polyunsaturated  fatty acids (n-3 LCPUFA), namely docosahexaenoic acid (DHA) in combination with  eicosapentaenoic acid (EPA) and, for ID 703, with docosapentaenoic acid (DPA).
The n-3 LCPUFA EPA, DHA and DPA are recognised nutrients and are measurable in foods by  established methods. They are well absorbed when consumed in the form of triglycerides. This  evaluation applies to EPA, DHA and, for ID 703, DPA from all sources with suitable bioavailability  in the specified amounts.
The Panel considers that the food constituent, EPA, DHA and DPA, which is the subject of the health  claims, is sufficiently characterised.
                 
                 
	        
        
        
        
        
                
2.6. Utrzymanie prawidłowego stężenia cholesterolu LDL we krwi (ID 527, 538, 1317, 1325,  4689)
                
                
                    The claimed effects are “cardiovascular health”, “heart health”, “cholesterol-lowering” and “for  cardiovascular system metabolism (cholesterol, triglycerides)”. The Panel assumes that the target  population is the general population.
In the context of the proposed wordings and clarifications provided by Member States, the Panel  assumes that the claimed effect refers to the maintenance of normal blood LDL-cholesterol  concentrations.
A claim on EPA and DHA and the maintenance of normal blood LDL-cholesterol concentrations has  already been assessed with an unfavourable outcome (EFSA Panel on Dietetic Products, Nutrition and  Allergies (NDA), 2009) and the references cited for this claim did not provide any additional  scientific data that could be used to substantiate the claim.
                 
                 
	        
        
Warunki i możliwe ograniczenia stosowania oświadczenia